Merck (MRK) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the approval of Enflonsia for the prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants during their first RSV season. The CHMP recommendation will now be reviewed by the European Commission for marketing authorization in the European Union, Iceland, Liechtenstein and Norway, and a final decision is expected before the end of the year.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Merck receives two positive EU CHMP opinions for Keytruda
- General Mills reports Q1 beat, Rithm to acquire Paramount Group: Morning Buzz
- Netflix upgraded, Five Below initiated: Wall Street’s top analyst calls
- Merck downgraded to Hold from Buy at Berenberg
- Trump’s UK Visit Prompts GSK to Commit $30B in U.S. Investment